Up-Regulation of miR-21, miR-25, miR-93, and miR-106b in Gastric Cancer

BACKGROUND: Differential expression profile of microRNAs (miRNAs) could be a diagnosis signature for monitoring gastric cancer (GC) progression. In this study, we focus on the comparison of expression levels of miR-21, miR-25, miR-93, miR-106b, and miR-375 during the sequential pattern of GC develop...

Descripción completa

Detalles Bibliográficos
Autores principales: Larki, Pegah, Ahadi, Alireza, zare, Ali, Tarighi, Shahriar, Zaheri, Mahrokh, Souri, Mojgan, Zali, Mohammad Reza, Ghaedi, Hamid, Omrani, Mir Davood
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Pasteur Institute 2018
Materias:
Full Length
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6305817/
https://www.ncbi.nlm.nih.gov/pubmed/29859516
http://dx.doi.org/10.29252/.22.6.367
Descripción
Sumario:BACKGROUND: Differential expression profile of microRNAs (miRNAs) could be a diagnosis signature for monitoring gastric cancer (GC) progression. In this study, we focus on the comparison of expression levels of miR-21, miR-25, miR-93, miR-106b, and miR-375 during the sequential pattern of GC development, including normal gastric, gastric dysplasia, and GC sample. METHODS: We used SYBR Green-based quantitative-PCR to quantify miRNAs expression. RESULTS: Our analysis revealed the increased expression levels of miR-21 (p = 0.034), miR-25 (p = 0.0003), miR-93 (p = 0.0406), and miR-106b (p = 0.023) in GC samples. In addition, GC patients with positive lymph node metastasis showed the up-regulation of miR-25, miR-93, and miR-106b (p < 0.05). CONCLUSION: Our findings suggested that the expression of miR-21, miR-25, miR-93, and miR-106b altered in GC, and some of them may be further investigated as biomarkers for GC early detection and prognosis prediction.

Ejemplares similares